312 related articles for article (PubMed ID: 25677589)
21. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
Johnbeck CB; Knigge U; Kjær A
Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
[TBL] [Abstract][Full Text] [Related]
22. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
23. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Shamim SA; Kumar A; Kumar R
PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675
[TBL] [Abstract][Full Text] [Related]
24. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R
Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680
[TBL] [Abstract][Full Text] [Related]
26. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
27. Contemporary nuclear medicine imaging of neuroendocrine tumours.
Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
[TBL] [Abstract][Full Text] [Related]
28. 68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.
Ambrosini V; Rubello D; Nanni C; Al-Nahhas A; Fanti S
Nucl Med Commun; 2008 May; 29(5):415-7. PubMed ID: 18391723
[No Abstract] [Full Text] [Related]
29. Nuclear imaging of neuroendocrine tumours.
Sundin A; Garske U; Orlefors H
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
[TBL] [Abstract][Full Text] [Related]
30. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
31. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
Ito T; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
[TBL] [Abstract][Full Text] [Related]
32. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
33. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center.
Nikolaou A; Thomas D; Kampanellou C; Alexandraki K; Andersson LG; Sundin A; Kaltsas G
J Endocrinol Invest; 2010 Dec; 33(11):794-9. PubMed ID: 20332708
[TBL] [Abstract][Full Text] [Related]
34. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours.
Chondrogiannis S; Grassetto G; Marzola MC; Rampin L; Massaro A; Bellan E; Ferretti A; Mazza A; Al-Nahhas A; Rubello D
Nucl Med Commun; 2012 Feb; 33(2):179-84. PubMed ID: 22083098
[TBL] [Abstract][Full Text] [Related]
35. ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
Ambrosini V; Campana D; Tomassetti P; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S52-60. PubMed ID: 22388622
[TBL] [Abstract][Full Text] [Related]
36. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.
Eriksson B; Bergström M; Orlefors H; Sundin A; Oberg K; Långström B
Q J Nucl Med; 2000 Mar; 44(1):68-76. PubMed ID: 10932603
[TBL] [Abstract][Full Text] [Related]
37. [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?].
Bombardieri E; Maccauro M; Castellani MR; Chiti A; Procopio G; Bajetta E; Seregni E
Minerva Endocrinol; 2001 Dec; 26(4):197-213. PubMed ID: 11782705
[TBL] [Abstract][Full Text] [Related]
38. Developments in PET for the detection of endocrine tumours.
Eriksson B; Orlefors H; Oberg K; Sundin A; Bergström M; Långström B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):311-24. PubMed ID: 15763703
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
40. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
